Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Duong, Vu
NCT04827745: Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL	Active, not recruiting	2	2	US	BLINCYTO (Blinatumomab)	University of Maryland, Baltimore	Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD)	06/25	08/27
NCT04050280: CLAG-GO for Patients With Persistent, Relapsed or Refractory AML	Recruiting	2	39	US	Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO), Mylotarg	University of Maryland, Baltimore, Hematologics, Inc	Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult	06/26	02/27
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN	Active, not recruiting	1/2	179	Europe, US	IMGN632	AbbVie	Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm	09/23	12/26
2087GCCC, NCT04666649: Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)	Active, not recruiting	1	27	US	Venetoclax and pegcrisantaspase	University of Maryland, Baltimore	Relapsed or Refractory Acute Myeloid Leukemia	09/24	09/25
NCT04953780: 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML	Active, not recruiting	1	6	US	Calaspargase pegol-mknl	University of Maryland, Baltimore	Acute Myeloid Leukemia	12/25	12/25